Castration-Resistant Prostate Cancer (CRPC) Live Forum for Urology Residents & Fellows (2017): CPS Protocol

The AUA recently released a report on the educational needs of urologists in the area of CRPC. These findings show strong support for the AUA to influence key stakeholders in urology residency programs in order to increase the amount of exposure residents receive in the area of CRPC. Additionally, the findings indicate that the AUA should look into the feasibility of developing stand-alone courses and educational materials specifically targeted to residents that covers the medical management of advanced prostate cancer.

Based on this educational need, AUA is launching a new educational initiative to focus on CRPC Resident & Fellow Training. Based on the documented need for additional education in this area, the AUA has developed multiple educational interventions to improve the urology resident and fellow's ability to care for patients with CRPC. The CRPC Resident & Fellow Training initiative is comprised of a variety of unique activities, including a self-assessment, pre-requisite work, a live forum and an online case-study activity. This activity will also provide each participant will access to patient education resources The initiative will offer the live one-day forum five times to reach residents and fellows across the country.

This initiative will provide a foundation of knowledge on CRPC and the ability to apply this knowledge into practice to improve the outcomes of their patients. As residency programs differ in what is offered, we recommend that each participant in this initiative successfully complete all of the activities. If a resident successfully completes all activities, they will receive a Certificate of Participation which they may share with their Residency Program Director.

All activities are free to urology residents and fellows.

Activity 4 – AUA Clinical Problem Solving (CPS) Protocol Online Activity

The AUA Clinical Problem Solving (CPS) Protocol is a very successful online series that is hosted on AUAUniversity. The AUA is developing a new and specific CPS Protocol on CRPC specifically for residents and fellows to support and enhance the learning from the live forum. This activity will allow the participant to apply the information they have learned on CRPC and focus on the practice-based application of the CRPC Guidelines.

Target Audience

  • Residents
  • Fellows

Learning Objectives

After completion of this activity, participants should be able to:

  1. Interpret and explain the appropriate diagnosis, prevention and treatment of the related guideline
  2. Perform appropriate methods of evaluation and management according to the guideline
  3. Analyze the risks and benefits for treatment according to the guideline
  4. Integrate AUA guidelines into clinical practice
Course summary
Available credit: 
  • 2.00 AMA PRA Category 1 Credit™
  • 2.00 Non-Physician Participation
Course opens: 
02/01/2017
Course expires: 
02/01/2020
Rating: 
0

Faculty Disclosures

Lee Richstone, MD: Nothing to disclose
Jennifer Yates, MD: Nothing to disclose   
                                        
Planner Disclosures

Education Council

Timothy Charles Brand, M.D.:
 Nothing to disclose
Anthony A. Caldamone MD: Nothing to disclose
Peter Robert Carroll, MD, MPH: NIH: Scientific Study or Trial; Department of Defense: Scientific Study or Trial; AUA Update: Leadership Position; Genomic Health: Scientific Study or Trial
Sam S. Chang, MD: astellas; Consultant or Advisor; NIH: Scientific Study or Trial; GLG: Consultant or Advisor; Janssen: Consultant or Advisor; tolmar: Consultant or Advisor
Matthew S. Christman MD: Nothing to disclose
Jody Donaldson: Nothing to disclose
Shelby Englert: Nothing to disclose
Matthew Thomas Gettman, MD: Nothing to disclose
Inderbir Singh Gill ,MD, M.Ch.: Nothing to disclose
Howard B. Goldman, MD: allergan: Consultant or Advisor; astellas: Consultant or Advisor; Medtronic: Consultant or Advisor, Meeting Participant or Lecturer, Scientific Study or Trial; Cook: Scientific Study or Trial; Nuvectra: Consultant or Advisor; Axonics: Consultant or Advisor
William C. Huang, MD: Photocure: Scientific Study or Trial; Karl Storz: Scientific Study or Trial
William C. Hulbert Jr. MD: Nothing to disclose
Brant Inman, M.D., MS, FRCSC: Dendreon: Scientific Study or Trial; Abbott Laboratories: Scientific Study or Trial; Genentech Inc: Scientific Study or Trial; Combat Medical: Consultant or Advisor; FKD Therapies: Scientific Study or Trial; AstraZeneca: Consultant or Advisor; Taris Biomedical: Consultant or Advisor
Mark L. Jordan MD,FACS: Nothing to disclose
Hari K. Koul, MSC,PHD: Novartis Pharmaceuticals: Consultant or Advisor; Urologic Research: Leadership Position; PLOS one: Leadership Position; OMICS group: Leadership Position; Open Access Publishing: Leadership Position, Health Publishing
Martin A. Koyle MD: Nothing to disclose
John Stephen Lam: Nothing to disclose
Yair Lotan ,MD: abbott: Scientific Study or Trial; Cepheid: Consultant or Advisor, Scientific Study or Trial; Pacific Edge: Scientific Study or Trial; FKD: Scientific Study or Trial; MDxHealth: Consultant or Advisor, Scientific Study or Trial; biocancell: Scientific Study or Trial; Genomic Health: Scientific Study or Trial; GenomeDx Biosciences Inc: Scientific Study or Trial; photocure: Consultant or Advisor, Scientific Study or Trial
Nicole Lara Miller ,MD: Boston Scientific Corporation: Consultant or Advisor, Meeting Participant or Lecturer; Practical Reviews In Urology: Health Publishing
Manoj Monga, MD, FACS: Fortec: Other; endourology society: Leadership Position
Victor William Nitti MD: Astellas: Health Publishing, Scientific Study or Trial; Allergan: Health Publishing, Scientific Study or Trial; Serenity Pharmeuticals: Investment Interest; Cook Myosite: Scientific Study or Trial; Medtronic: Scientific Study or Trial
Christopher Porter, MD: Nothing to disclose
Gail S. Prins PhD: Nothing to disclose
Ganesh V. Raj MD, PhD: Ptares: Owner, Product Development; C-diagnostics corp: Consultant or Advisor, Investment Interest; amgen: Meeting Participant or Lecturer; Johnson and Johnson: Consultant or Advisor, Owner, Product Development; Astellas: Meeting Participant or Lecturer; ASTELLAS: Consultant or Advisor, Meeting Participant or Lecturer; Janssen: Owner, Product Development; BAYER: Consultant or Advisor, Meeting Participant or Lecturer; SANOFI: Consultant or Advisor, Meeting Participant or Lecturer; Gaudium: Leadership Position, Investment Interest, Owner, Product Development; Medivation: Consultant or Advisor, Meeting Participant or Lecturer, Scientific Study or Trial
Jay D. Raman, MD: American Kidney Stone Management: Investment Interest; Pacific Edge Biotechnology: Consultant or Advisor, Scientific Study or Trial
Lee Richstone, MD: Nothing to disclose
Heather Schultz, NP: SUNA: Meeting Participant or Lecturer
Karl-Dietrich Sievert ,MD, PhD: AMS: Meeting Participant or Lecturer; Medtronics: Meeting Participant or Lecturer, Scientific Study or Trial; Allergen: Consultant or Advisor, Meeting Participant or Lecturer, Scientific Study or Trial; Neotract: Meeting Participant or Lecturer; Stimguard: Meeting Participant or Lecturer, Scientific Study or Trial
Joseph A. Smith Jr.,MD: Nothing to disclose
Ryan Patrick Terlecki, MD, FACS: American Medical Systems: Consultant or Advisor, Other; Allergan: Scientific Study or Trial
Edouard John Trabulsi, MD: Nothing to disclose
 

Method of Participation

Learners will participate in this interactive online educational activity by completing a pre-test, reading the AUA Guideline, complete the slides and case studies, answering multiple choice questions, examining patient tools and resources and completing the post-test and evaluation. To claim CME credit for this enduring material, learners must complete the posttest, passing with 80% accuracy and submit the program evaluation.

Estimated time to complete each activity: 2.0 hours

Release Date: June, 2017
Expiration Date: June, 2020

AUA Disclosure Policy

All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) participating in an educational activity provided by the AUA are required to disclose to the provider any relevant financial relationships with any commercial interest. The AUA must determine if the individual’s relationships may influence the educational content and resolve any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.

Resolution of Identified Conflict of Interest

All disclosures will be reviewed by the program/course directors or editors for identification of conflicts of interest. Peer reviewers, working with the program directors and/or editors, will document the mechanism(s) for management and resolution of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to resolve conflict of interest:

  • Peer review for valid, evidence-based content of all materials associated with an educational activity by the course/program director, editor, and/or Education Content Review Committee or its subgroup
  • Limit content to evidence with no recommendations
  • Introduction of a debate format with an unbiased moderator (point-counterpoint)
  • Inclusion of moderated panel discussion
  • Publication of a parallel or rebuttal article for an article that is felt to be biased
  • Limit equipment representatives to providing logistics and operation support only in procedural demonstrations
  • Divestiture of the relationship by faculty

Accreditation Statement

The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

The American Urological Association designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Evidence-Based Content

It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.

Off-label or Unapproved Use of Drugs or Devices

It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias. The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the product prescribing information for full disclosure of approved uses.

Disclaimer

The opinions and recommendations expressed by faculty, authors and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the AUA.

Acknowledgements

This educational series is supported by independent educational grants from:

  • AbbVie
  • Astellas
  • Bayer Healthcare Pharmaceuticals, Inc.
  • Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
  • Medivation, Inc., a Pfizer company
  • Sanofi Genzyme

Reproduction Permission

Reproduction of written materials developed for this AUA course is prohibited without the written permission from individual authors and the American Urological Association.

AUA Privacy and Confidentiality Policy

The AUA Privacy and Confidentiality Policy can be found at: www.auanet.org/education/confidentiality-statement.cfm

Contact Information

American Urological Association
Office of Education
1000 Corporate Blvd
Linthicum, MD 21090

Toll Free (U.S. only): 1-866-RING AUA (1-866-746-4282)
Phone: 410-689-3700
Fax: 410-689-3800

CME Information

For all inquiries regarding CME credit email: education@AUAnet.org

    Available Credit

    • 2.00 AMA PRA Category 1 Credit™
    • 2.00 Non-Physician Participation

    Accreditation Period

    Course opens: 
    02/01/2017
    Course expires: 
    02/01/2020
    Please login or register to take this course.